Chinese Herbal Medicine (Xiaoaiping) Injections for Chemotherapy-Induced Thrombocytopenia: A Randomized, Controlled, Multicenter Clinical Trial. [PDF]
J Altern Complement Med, 2019 Qi S +9 more
europepmc +1 more source
Elevated BNP caused by recombinant human interleukin-11 treatment in patients with chemotherapy-induced thrombocytopenia. [PDF]
Support Care Cancer, 2019 Liu NW +6 more
europepmc +1 more source
The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. [PDF]
Haematologica, 2018 Al-Samkari H +3 more
europepmc +1 more source
Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. [PDF]
Cochrane Database Syst Rev, 2017 Zhang X, Chuai Y, Nie W, Wang A, Dai G.
europepmc +1 more source
Related searches:
Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia
Expert Review of Hematology, 2021Introduction: Chemotherapy-induced thrombocytop enia (CIT) is a common complication of cancer treatment causing chemotherapy delays, dose reductions, and treatment discontinuation, negatively impacting treatment outcomes and putting patients at risk for bleeding complications.
Hanny Al-Samkari, Gerald Soff
exaly +3 more sources
Chemotherapy induced thrombocytopenia in pediatric oncology
Critical Reviews in Oncology/Hematology, 2016Thrombocytopenia has long been recognized as a significant problem of cancer therapy, but there is still lack of consensus about the optimal approach to prophylaxis and/or treatment of this important complication. In pediatric oncology, since there are very few studies dedicated to this problem, the knowledge gap is even larger and no final conclusions
SAMVEL Danelyan +2 more
exaly +3 more sources
Romiplostim for management of chemotherapy-induced thrombocytopenia
Supportive Care in Cancer, 2014Chemotherapy-induced thrombocytopenia (CIT) can cause delay or reduction in subsequent courses of chemotherapy. Here, we report on a series of 20 patients who had protracted CIT and were treated with romiplostim, a thrombopoietin receptor agonist.We performed a retrospective review of the use of romiplostim for dose-limiting CIT at Memorial Sloan ...
M Lunning
exaly +3 more sources
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
New England Journal of MedicineChemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse outcomes. No widely available therapies are approved for CIT.We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial involving patients with ...
Hanny Al-Samkari +12 more
openaire +3 more sources
The effect of lithium carbonate on chemotherapy‐induced neutropenia and thrombocytopenia
American Journal of Hematology, 1984AbstractLithium carbonate ameliorates neutropenia associated with cancer chemotherapy. The effect of lithium on platelet suppression has not, however, been well established. In the present study, five patients with ovarian carcinoma received daily lithium during alternate cycles of treatment with hexamethylmelamine, cyclophosphamide, adriamycin, and ...
C M, Richman +3 more
openaire +2 more sources
Interleukin 3 in the treatment of chemotherapy induced thrombocytopenia.
Oncology Reports, 1998We enrolled 19 cancer patients (11 females, 8 males) with thrombocytopenia after standard dose of chemotherapy to receive IL3 10 mg/kg/day s.c. until hematologic recovery. Therapeutic success was obtained in 69.6% of cycles; a major response in 39.3% and a minor response in 30.3% of cycles. We obtained the best results in case of platelet count
V, Leonardi +3 more
openaire +2 more sources